1	Improving Diagnostic Precision: Urine Proteomics Identifies Promising Biomarkers for
2	Necrotizing Enterocolitis
3	Stephen Mackay <sup>1</sup> , Lauren C. Frazer <sup>1</sup> , Grace K. Bailey <sup>1</sup> , Claire M. Miller <sup>1</sup> , Qingqing Gong <sup>2</sup> , Olivia
4	N. DeWitt <sup>2</sup> , Misty Good <sup>1*</sup>
5	
6	<sup>1</sup> Division of Neonatal-Perinatal Medicine, Department of Pediatrics, University of North Carolina
/	
8	<sup>2</sup> Division of Newborn Medicine, Department of Pediatrics, Washington University School of
9	Medicine, St. Louis, MO 63110
10	
11	*Correspondence:
12	Misty Good, MD, MS
13	Division Chief, Neonatal-Perinatal Medicine
14	Department of Pediatrics
15	The University of North Carolina at Chapel Hill
16	101 Manning Drive Campus Box 7596
17	Chapel Hill, NC 27599
18	Office: 984.974.5063, Fax: 984.974.7857
19	Email: mistygood@unc.edu
20	
21	

## 22 Abstract

23	Background: Necrotizing enterocolitis (NEC) is a severe intestinal disease that primarily
24	impacts preterm infants. Current diagnostic tools are inadequate, so urine proteomics was
25	performed for patients with and without NEC to identify putative biomarkers.
26	Research design and methods: The abundance of urinary proteins detected using an
27	aptamer-based microarray was compared for infants with NEC ( $n=20$ ) and controls, age-
28	matched ( $n=8$ ) or self-matched ( $n=12$ ). Spearman $r$ correlation and hierarchical cluster analysis
29	were performed. The area under the curve (AUC) was calculated for receiver operator
30	characteristic curves (ROC).
31	<b>Results</b> : Ninety-nine proteins differed in NEC vs. controls based on median fold change (Log <sub>2</sub> $\pm$
32	1.1) and significance ( $P < 0.05$ ). Patterns of abundance were consistent for both types of
33	matching, and samples clustered based on NEC severity. Two panels were built to differentiate
34	between infants with and without NEC. Panel 1 included proteins associated with
35	inflammation/NEC and produced by the intestinal epithelium (REG1B, REG3A, FABP2, DEFA5,
36	AUC 0.90). Panel 2 consisted of proteins with the largest fold change between NEC vs. controls
37	and the highest individual AUC values (REG1B, SSBP1, CRYZL1, ITM2B, IL36B, IL36RN, AUC
38	0.98).
39	Conclusions: Urine proteins significantly differ between infants with and without NEC, which
40	supports their potential as future biomarkers.
41	

42 Keywords: Aptamer-based microarray, Biomarker, Necrotizing enterocolitis, Neonatal Intestine,
43 Preterm, Urine Proteomics.

#### 45 Background

46 Necrotizing enterocolitis (NEC) is a rapidly progressive intestinal disease that occurs 47 primarily in preterm and low birth weight neonates and has an incidence of ~7% for neonates born at < 32 weeks gestation [1]. The first symptoms of NEC, such as feeding intolerance and 48 abdominal distension, can be difficult to distinguish from other etiologies; however, within hours 49 50 of disease onset, an infant with NEC can progress to needing emergency surgery or death. The 51 rapidity of this clinical decompensation is why an early and accurate diagnosis of NEC is essential. Currently, NEC is diagnosed using imaging modalities such as abdominal X-rays 52 53 and/or ultrasound combined with physical exams and laboratory tests, but these tools have 54 inadequate sensitivity and specificity, particularly early in the disease course [2]. Unfortunately, 55 no biomarkers for NEC have been implemented in routine clinical practice, which could improve upon some of the current diagnostic limitations. 56

Identification of biomarkers for NEC has been hindered by a multitude of factors, with the primary barrier being an incomplete understanding of disease pathogenesis. NEC is thought to result from a poorly controlled immune response in the neonatal intestine in the setting of a dysbiotic microbiome. This inflammation leads to intestinal epithelial injury, loss of mucosal barrier integrity, and, ultimately, tissue necrosis [3-6]. The precise factors that induce and exacerbate disease remain an area of active investigation, and that knowledge barrier continues to impede biomarker development.

64 Several potential biomarkers have been identified for NEC, including proteins/peptides 65 [7,8], metabolites [9], and non-coding RNAs [10,11], but reproducibility and validation of the 66 biomarkers in large cohorts have not been conclusive. In addition, some urinary biomarkers for

NEC have been identified, such as fatty acid binding protein-2 (FABP2) [12]; however, these 67 markers are not in use clinically, as normalization of urine samples has been problematic [12]. 68 69 Optimally, a biomarker for NEC would identify infants early in the disease process and reliably 70 differentiate between neonates with NEC and other intestinal or systemic inflammatory 71 pathologies. In addition, an ideal biomarker would be validated for use with biological specimens 72 that are readily available and non-invasively acquired, given the difficulties associated with 73 acquiring specimens from medically fragile preterm neonates. To overcome the difficulty in obtaining a large number of infants with NEC at one center, we established the multi-center 74 NEC Biorepository to identify biomarkers of disease [13,14]. 75

76 With improvements in technology, the identification of new biomarkers for NEC is now a 77 distinct possibility. Traditional methods for biomarker identification include quantitative and 78 gualitative analysis of proteins and metabolites using untargeted gas or liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Recently, aptamer-based proteomic 79 80 screens using large, highly selective libraries have been utilized to screen samples for 81 biomarkers in various tissue and biological specimens, including serum, stool, and urine [15-17]. 82 Compared to LC-MS/MS, aptamer-based scans are better able to detect small proteins [18], which presents the opportunity to detect new biomarkers for NEC. 83

In this study, we utilized aptamer-based proteomics technology (SomaScan<sup>®</sup>) to measure the relative abundance of over 7000 proteins in the urine of infants with NEC and controls. We identified ninety-nine proteins that differed between the groups and performed a detailed analysis of protein abundance, patterns across samples, disease severity, and diagnostic utility. In addition, we identified two protein panels and a pair of proteins that effectively differentiate between infants with NEC and controls. This study provides the

- 90 foundation for future work investigating urine biomarkers for NEC in a larger population of
- 91 preterm infants and provides an advance toward identifying urgently needed biomarkers for this
- 92 devastating disease.
- 93 Methods
- 94 Study design

95 Samples were prospectively collected from infants admitted to the St. Louis Children's 96 Hospital Neonatal Intensive Care Unit (NICU) in St. Louis, Missouri, USA. Enrollment of infants 22 to 42 weeks gestation was conducted according to protocols approved by the Washington 97 University in St. Louis School of Medicine Institutional Review Board (IRB protocol numbers 98 201706182 and 201802101). Infants with major congenital anomalies were excluded. For the 99 100 current study, we included infants initially enrolled as controls and then subsequently developed NEC (self-matched, n = 12). We also analyzed a cohort of age-matched infants (n = 8 pairs), 101 which included infants enrolled at the time of NEC diagnosis (n = 8) and their age-matched 102 controls (n = 8). Infants with urinary tract infections were excluded. The cohort was comprised of 103 104 infants born between 24 and 36 weeks gestation (n = 28) (**Table 1**) and modified Bell's staging 105 was used to categorize NEC severity [19-21].

106

#### 107 Sample collection

Urine samples were collected by placing sterile gauze in a clean diaper. Urine-saturated
 gauze was then collected at a routine care time, placed in a 10 mL syringe, and stored at 4°C
 until processed by laboratory staff 1-2 times per day. Urine was subsequently extracted from the

- gauze by squeezing the syringe, aliquoted into cryotubes, and stored at -80°C until analysis.
- 112 Samples with visible stool contamination were discarded.
- 113
- 114 Proteomics assays
- 115 Sample preparation for SomaScan<sup>®</sup> and ELISA

Frozen urine samples (-80°C) were thawed in a water bath for 15 min at 37°C and mixed 116 117 by pipetting before combining 216 µL urine with 9 µL of 1 M Tris-HCl to a final concentration of 40 mM. The samples, in two 100 µL volumes, were desalted by buffer exchange using a Zeba<sup>™</sup> 118 7 kDa MWCO Spin column desalting plate (ThermoFisher Scientific, Waltham, MA) according to 119 the manufacturer's guidelines. Desalting plates reached room temp before centrifuging at 1000 120 121 x q for 2 min to remove the storage buffer. A 250 µL volume of assay buffer was added to the resin beds and centrifuged at 1000 x q for 2 min. This was repeated three times. Protein 122 concentration was determined using a Pierce<sup>™</sup> Micro BCA<sup>™</sup> protein assay kit (ThermoFisher 123 124 Scientific, Waltham, MA) according to the manufacturer's instructions.

125

## 126 SomaScan<sup>®</sup> proteomic assay

127 The differential abundance of proteins in urine samples was measured using an 128 aptamer-based SomaScan<sup>®</sup> 7,000 protein microarray assay kit v4.1 (SomaLogic<sup>®</sup>, Boulder, CO, 129 USA) as previously described [22]. Briefly, the microarray screened proteins using "Slow Off-130 Rate Modified Aptamers" (SOMAmers<sup>®</sup>) that were selected against protein epitopes using the 131 Systematic Evolution of Ligands by Exponential Enrichment (SELEX) [22]. The scan utilized a

132	resolution of 5 $\mu$ m and detected Cy3 fluorescence expressed as relative fluorescence units
133	(RFU). Off-scanner raw signal values were calibrated, standardized, and scaled at multiple
134	dilution categories, namely S1 (61% of proteins), S2 (~38.5%), and S3 (0.4%), where S1 targets
135	low abundant proteins, and S3 targets proteins close to saturation. RFU readouts were
136	analyzed using the Agilent Feature Extraction v10.7.3.1 (Agilent Technologies, Santa Clara,
137	CA). Differential abundance was calculated using the SomaScan <sup>®</sup> statistical analysis tool v4.1
138	and fitted as a linear model of the signal data and an empirical analysis by a Bayesian statistical
139	test for group comparisons.
140	

141 ELISA

Proteins selected for ELISA validation included REG1B (EH389RB, ThermoFisher
Scientific, Waltham, MA), DEFA5 (HUFI01588, AssayGenie, Dublin, Ireland), FABP2
(EHFABP2, ThermoFisher Scientific, Waltham, MA), and REG3A (EH390RB, ThermoFisher
Scientific, Waltham, MA). Urine samples were prepared, desalted, and quantified as described
above. For each sample, triplicate measurements of 0.2, 2, 10, or 20 µg total protein were
plated based on anticipated protein abundance to fit within the range of the standard curve for
each ELISA.

149

150 Ingenuity Pathway Analysis

Network analysis and pathway enrichment were predicted using Ingenuity Pathway
 Analysis (IPA) (QIAGEN digital insights, Redwood City, CA, USA, accessed on June 20, 2023).

153 IPA was used to generate a core analysis using all 99 differentially abundant proteins (**Table 2**) 154 based on differential median fold change expression ( $Log_2 \pm 1.1$ ) and Mann-Whitney U-test 155 significance (P < 0.05) cut-offs.

156

#### 157 Statistical analysis

Proteins above a Log<sub>2</sub> median fold change RFU of 1.1 and a statistical significance of P 158 159 < 0.05 for the comparison between samples from infants with NEC and controls were selected for detailed analysis. Samples were analyzed for the influence of multiple comparisons using a 160 161 false discovery rate (FDR) of < 0.05. Volcano plots, hierarchical cluster analysis, and Spearman's *r* correlation matrices were performed using Log<sub>2</sub> RFU median fold change values. 162 Log<sub>10</sub> RFU values were used for comparative statistical analysis for violin plots and receiver 163 operator characteristics (ROC). Statistical significance was determined by a Mann-Whitney U-164 165 test, non-parametric Wilcoxon test, or Kruskal Wallis as indicated. Combined ROC curves were 166 generated using multiple logistic regression. Comparative statistical analysis was performed using GraphPad 9.3.1 (San Diego, USA). Hierarchical clustering was generated in R-studio 167 168 version 4.2.0 using the "heatmap.2" package by Ward clustering.

169

170 Results

## 171 Cohort characteristics

The cohort included infants (*n* = 28) born between 24 and 36 weeks gestation and
divided into age- and self-matched cohorts (**Table 1**). For the age-matched cohort, infants were

enrolled at the time of NEC diagnosis (n = 8) and matched with infants who did not develop NEC (controls, n = 8). For the self-matched cohort, infants were initially enrolled as controls but then developed NEC (n = 12). Samples obtained before NEC diagnosis were used as the control for this group, with six days being the shortest interval between a control sample and a diagnosis of NEC.

179

## 180 **Qualitative and quantitative proteomic analysis of urine proteins**

A total of 7596 proteins were screened in the urine samples using an aptamer-based 181 proteomics microarray (SomaScan<sup>®</sup>). For the age-matched cohort, 150 urine proteins were 182 significantly different between the infants with NEC and controls, based on Log<sub>2</sub> median fold 183 change RFU of  $\pm$  1.1 and Mann-Whitney U-test of *P* < 0.05 (**Figure 1A**). For the self-matched 184 cohort, 360 urine proteins were differentially abundant in the control compared to the NEC 185 samples (Figure 1B). There were 99 proteins shared between the age- and self-matched 186 187 groups, and these will be the focus of the remainder of the analysis (Figure 1C). Of these 99 proteins, 35 were increased, and 64 were decreased between infants with NEC and their 188 189 respective controls. A summary of the identified proteins in the combined cohort is provided in 190 **Table S1**. Due to the small sample size of the cohort, only 10 proteins of the 7596 in the microarray survived multiple testing correction by false discovery rate (FDR < 0.05). Of the 191 192 proteins that survived this correction, interleukin 36B (IL36B, FDR = 0.024) and interleukin 36 receptor antagonist (IL36RN, FDR = 0.024) were in the subset of proteins that were significantly 193 194 different between the infants with NEC and controls.

195 We next identified two protein panels of interest for further analysis. Protein panel one 196 consisted of four proteins chosen for their primary localization within the intestine and previously 197 observed association with NEC and/or inflammation (**Table 2**). These include regenerating 198 family member 1 beta (REG1B), regenerating islet-derived protein 3 alpha (REG3A), intestinal 199 fatty acid binding protein 2 (FABP2), and defensin 5 alpha (DEFA5). Protein panel 2 consisted of proteins chosen based on the magnitude of the fold change between patients with NEC and 200 201 controls, as well as the best area under the curve (AUC) values (Table 2). Panel 2 included REG1B (also in panel 1), single-stranded DNA binding protein 1 (SSBP1), crystallin zeta-like 1 202 203 (CRYZL1), integral membrane protein 2B (ITM2B), IL36B, and IL36RN.

204 We analyzed the association between the relative protein levels for the most differentially 205 abundant proteins using an inter-protein Spearman's r correlation matrix (Figure 2A). With a 206 focus on our protein panels, we found that for panel 1, DEFA5 and REG3A had the strongest correlation (r = 0.83) (Figure 2B). In addition, REG3A (r = 0.57) and DEFA5 (r = 0.46) had 207 208 strong positive correlations to REG1B (Figure 2B). For protein panel 2, there was a strong 209 negative correlation with IL36RN with REG1B (r = -0.63) (Figure 2C). In addition, SSBP1 210 correlated positively with ITM2B (r = 0.62) and negatively with CRYZL1 (r = -0.52) and IL36B (r= -0.45) (Figure 2C). 211

We next used hierarchical cluster analysis to visualize patterns in protein abundance across patient pairs and disease severity (**Figure 3**). We found that the pattern of relative fold change of the proteins was consistent across samples. In addition, age-matched and selfmatched samples did not cluster together, but samples did cluster based on disease severity, with noted clustering of samples from patients with Bell's stage III NEC (**Figure 3**).

217

#### 218 Analysis of protein abundance and comparison based on disease severity.

Violin plots were used to visualize the protein abundance in urine samples for the 219 proteins in panel 1, with significant differences noted between controls and patients with NEC 220 (Figure 4A). We further analyzed the differences in urine protein abundance based on disease 221 222 severity as defined by modified Bell's stage (Figure 4B). REG1B was significantly increased in 223 infants with NEC Bell's stage II compared to controls (P < 0.01) as well as in Bell's stage III vs. controls (P < 0.01). REG3A and DEFA5 were significantly increased in the urine of infants with 224 NEC Bell's stage III vs. controls (REG3A: P < 0.0001, DEFA5: P < 0.0005) and in Bell's stage II 225 compared to Bell's stage III (REG3A: P < 0.01, DEFA5: P < 0.01). FABP2 was only significantly 226 227 increased Bell's stage III vs. controls (P < 0.05).

228 ELISAs were used to validate the relative protein abundance detected with the protein microarray. We selected the proteins in panel 1, REG1B, REG3A, FABP2, and DEFA5 229 (Supplementary Figure S1) for validation. REG1B (Figure S1A) and DEFA5 (Figure S1C) 230 231 were both significantly increased in NEC relative to controls; however, REG3A (Figure S1B) and FABP2 (Figure S1D) were not significantly different in NEC compared to controls 232 (Supplementary Table S2). This likely occurred because levels of the urine proteins were 233 below the limit of detection for the ELISAs for some patients, which resulted in an inability to 234 235 detect differences between patients with NEC and controls. These assays were limited by the 236 volume of urine obtainable from preterm neonates and the low concentration of the proteins of 237 interest. Thus, the microarray data was used for the remainder of the analysis due to increased sensitivity at lower protein concentrations. 238

Analysis of the ability of these proteins to serve as potential biomarkers was performed by calculating the AUC (**Table 2** and **Figure 4C**). Values above 0.7 are considered acceptable, and above 0.8 are considered excellent for a diagnostic test. REG1B (0.82, 95% CI 0.69-0.95) and REG3A (0.79, 95% CI 0.69-0.95) were the most effective at differentiating between patients with NEC and controls (**Figure 4C**).

We performed a similar analysis for the proteins in panel 2. The RFU data for the urine samples from patients with NEC and controls is shown in **Figure 5A**. We also analyzed the ability of these proteins to differentiate between patients based on NEC severity (**Figure 5B**). We found that CRYZL1, ITM2B, IL36B, and IL36RN were significantly different between infants with Bell's stage II NEC relative to controls (P < 0.05). SSBP1 (P < 0.005) and IL36B (P < 0.05) were significantly different between infants with NEC Bell's Stage II and III.

ROC curves were generated for all proteins in panel 2. All of the proteins in panel 2 were
effective at differentiating between infants with NEC and controls (Figure 5C). IL36B (0.86, 95%
CI 0.74-0.98) and IL36RN (0.91, 95% CI 0.82-0.99) had the best AUC values and have the
potential to serve as excellent diagnostic tests.

254

#### 255 Diagnostic utility of protein panels

We generated combined ROC curves for groups of proteins to determine if this would improve their diagnostic utility as urine biomarkers (**Figure 6**). We found that protein panel 1 (**Figure 6A**, AUC 0.9, 95% CI 0.8-1), protein panel 2 (**Figure 6B**, AUC 0.98, 95% CI 0.95-1), and the combination of IL-36B and IL36RN (**Figure 6C**, AUC 0.94, 95% CI 0.86-1) had an outstanding ability to differentiate between infants with NEC and controls.

#### 261 Upstream regulators and statistical enrichment

262	Ingenuity pathway analysis (IPA) was used to predict activated or inhibited upstream
263	regulators and signaling pathways. IPA predicts differentially activated regulators measured by
264	downstream enrichment scores (overlap <i>P</i> -value) and activation states (activation <i>z</i> -score) [23].
265	Upstream regulator analysis (URA) predicts direct relationships between upstream regulators
266	and downstream molecules using the protein dataset. Causal analysis (CNA) tools further
267	predict upstream master regulators that may have multiple indirect relationships, nodes, and
268	links. Upstream regulators of interest (linked to inflammation) by URA and CNA were predicted
269	and summarized in Table 3.

URA predicted several direct regulators based on the downstream status of the differentially abundant proteins identified in the urine samples. This includes regulators of lipid metabolism, sterol regulatory element binding protein 1 (SREBF1, z = 1.95, P = 0.00015), and retinoic acid receptor alpha (RXRA, z = 1.94, P = 0.00794) (**Table 3**). In addition, the polyfunctional cytokine IL-22 (z = 1.96, P = 0.00091) was predicted as activated based on the differential abundance of REG1B (+), REG3A (+), LBP (+), and TGM3 (-) (**Supplementary Figure S2, Table 3**).

277 CNA includes indirect relationships and linked nodes to identify upstream-master 278 regulators (**Table 3**). Predicted master regulators included: TNF receptor-associated factor 1B 279 (TRAF2) (z = 2.353, network bias corrected P = 0.0003), which plays a role in NFkB and JNK 280 signaling pathways [24], mRNA decay activator protein ZFP36 (z = 2.263, network bias 281 corrected P = 0.0153), which is involved in cytokine degradation and regulates the TNF-alpha 282 feedback loop through mRNA destabilization [25,26], Endoribonuclease ZC3H12A (z = 2.191,

network bias corrected P = 0.043), and IL-22 (z = 2.0, network bias corrected P = 0.0171).

STAT3, which is activated by IL-22 and other cytokines, was upstream of several differentially

abundant proteins in this study (**Supplementary Figure S2, Table 3**).

286

#### 287 Discussion

In this study, we used an aptamer-based protein microarray to successfully identify a subset of urine proteins that differentiated between infants with and without NEC. The validity of our data was supported by the fact that patterns of relative protein abundance in the urine were consistent across both age- and self-matched cohorts. In addition, the protein levels in the urine of these patient cohorts clustered based on the severity of NEC. Our identified biomarker panels had excellent diagnostic potential based on AUC values, supporting further studies investigating these proteins of interest as potential biomarkers.

295 Our study focused on urine as the biological source for biomarker testing, given that it is an easily obtainable specimen even for tiny preterm neonates. Unfortunately, the detection of 296 297 biomarkers in urine adds additional analytical challenges due to sample-to-sample biological 298 variability. This includes significant variability in hydration states, glomerular filtration rates 299 (GFR), and differential abundance in carrier proteins and metabolites [27]. The accurate quantitation of differentially abundant proteins measured in urine is likely improved using a 300 301 reference marker. Typical urine reference markers require a constitutively expressed gene or 302 metabolite unaffected by the disease. Studies have tried to identify a reliable normalization reference using urinary proteins or peptides to adjust for urinary dilution [7]. These have 303 304 included serum albumin, collagen, and urine creatinine; however, protein and metabolite

variability based on the developmental age of neonates complicates normalization [28]. For
example, urine albumin and creatinine concentrations in neonates have been shown to be
inconsistent in preterm infants [29]. The consistency of our protein abundance patterns with two
different patient matching strategies and across a range of corrected gestational ages indicates
that these technical issues were likely minimized by using equivalent protein loading, as was
performed in our studies.

311 Based on published data, the likely intestinal origin of many of the proteins we detected provides another degree of complexity, as it requires proteins or peptides to enter the 312 bloodstream from the intestine and be filtered by the glomeruli in the kidney to be identified in 313 314 the urine. In addition, biomarkers need to distinguish NEC from non-specific inflammation in the 315 kidneys and urinary tract to have clinical significance. In this study, known biomarkers for urinary tract infections [30] and acute kidney injury [31], specifically NGAL (Lipocalin-2) and CST3 316 (Cystatin C), were not significantly abundant. In addition, the consistency of protein abundance 317 318 patterns across matching strategies and the clustering of patients based on disease severity 319 supports a NEC-specific protein signature independent of renal complications.

In this study, we developed two protein panels and identified a pair of proteins with excellent AUC values for diagnostic studies. Using a protein panel increases the power of a diagnostic test to accurately discriminate between healthy and diseased states. Although a single disease biomarker would be optimal, this is likely unfeasible given the complexity of the pathogenesis of NEC. Below, we discuss the specific proteins we incorporated into our panels.

325 REG1B and REG3A

326 Regenerating islet-derived proteins (REGs) have multifunctional roles in cellular 327 processes, including promoting differentiation, increasing cellular proliferation, preventing apoptosis, and enhancing host defense [32]. REG proteins (18-19 kDa) have been discovered 328 329 in multiple tissues and diseases, and they are typically expressed at sites of inflammation [33]. 330 REG1B and REG3A recognize bacterial peptidoglycan and reduce bacterial membrane integrity [34]. They are increased in inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) 331 332 [35]. REG1B expression is also increased in the intestine during NEC [36]. In addition, increased REG1B expression drives intestinal crypt regeneration [37]. REG3A has anti-333 334 apoptotic effects and increases enterocyte viability by reducing caspase cleavage [38]. REG1B 335 [39] and REG3A [40] have been identified as potential stool biomarkers for enteropathy and 336 environmental enteric dysfunction (EED). Finally, REG1B and REG3A are induced by the IL-22 337 signaling pathway [41], which is protective in the intestine of mice during experimental NEC [42]. FABP2 338 339 Fatty acid binding protein 2 (FABP2) is a 15 kDa enterocyte-specific carrier protein 340 involved in intracellular fatty acid translocation across the gut barrier [43]. FABPs are subdivided into intestinal (FABP2), hepatic (FABP1), and adipose (FABP4) variants based on localization. 341 342 FABP2, FABP1, and FABP4 were all differentially abundant in our proteomic assay (Supplementary Table 1). FABP2 has previously been identified as differentially abundant 343 during intestinal barrier dysfunction [44] and, specifically, NEC in several biomarker studies of 344 345 stool and urine [45]. A clinical metadata study showed a high FABP2 level was an indicator of NEC, but many studies were limited in sample size and had difficulty consistently normalizing

347 urine samples by creatinine [12].

## 348 DEFA5

349	Human $\alpha$ -defensin (DEFA5) (10 kDa) is a powerful antimicrobial host defense protein
350	[46]. It is primarily expressed by intestinal Paneth cells and stored intracellularly as a zymogen.
351	After secretion, DEFA5 is activated by trypsin and regulated by Paneth cell-derived serine
352	protease inhibitors, which play a role in selectively maintaining gut microbiome diversity. One
353	study has linked increased expression with urinary tract infections [47]. Increased DEFA5 has
354	previously been detected in the stool of infants with NEC via proteomics [48] and in intestinal
355	samples resected from infants with NEC via RNA sequencing [49]. In addition, altered stool
356	DEFA5 methylation patterns have been observed during NEC [50].
357	SSBP1
358	Single-stranded DNA binding protein 1 (SSBP1) is a ubiquitously expressed protein
359	involved in mitochondrial biogenesis. Mitochondrial damage, through the presence of
360	mitochondrial DNA and proteins in urine, has been used as a marker for tissue damage during
361	inflammation [51]. In addition, SSBP1, through heat shock factor 1 (HSF1) signaling, has been
362	linked to increased expression of heat shock protein 70 (Hsp70) [52]. Hsp70 protects cells from
363	proteolytic stress and regulates pro-inflammatory Toll-like receptor (TLR)-induced cytokines [53].
364	In enterocytes, activation of TLR4 leads to upregulation of Hsp70, and Hsp70 signaling has
365	been identified as a potential counter-regulatory mechanism that opposes TLR4 signaling during

366 NEC [54].

367 CRYZL1

368 Crystallin zeta-like 1 (CRYZL1) is ubiquitously expressed and shares sequence 369 homology with zeta crystallin or quinone oxidoreductase 1 (NQO1). While the role of CRYZL1 is

370 unclear, NQO1 protects against cellular damage by acting as a redox switch interacting with

- 371 multiple proteins, mRNA, and NADH [55]. Upregulation of *Nqo1* expression has been
- associated with protection from NEC-like injury in rats [56].
- 373 ITM2B
- 374 Integral membrane protein 2B (ITM2B) is found in all tissue types. Its exact function
- needs to be delineated, although it is thought to play a role in apoptosis, mitochondrial

homeostasis, and processing of amyloid precursor proteins [57].

377 IL36B and IL36RN

378 Interleukin 36 (IL-36) proteins are a family of inflammatory cytokines and consist of agonists IL36 ( $\alpha$ ,  $\beta$ ,  $\gamma$ ) and a receptor antagonist, IL36RN (IL36Ra). IL-36 dysregulation is 379 380 associated with inflammatory diseases, including psoriasis, arthritis, and IBD [58]. In addition, 381 IL-36 regulates both immune and non-immune cells in a feedback loop where IL-22, IL-17A, and TNFα induce all three IL-36 family cytokines, and IFNγ is selective for inducing IL36B [59]. 382 Interestingly, in mice with NEC, increased IL36B was detected only in the ileum, and an 383 increased IL36B: IL36RN ratio was associated with NEC [60]. In our study, the relative decrease 384 385 in IL36RN is consistent with increased inflammation, whereas the reduction in IL36B is not 386 expected and needs further exploration in mechanistic studies.

387 Upstream regulator network analysis

IPA identified several potential upstream and mechanistic regulators. Notably, IL-22 was
 predicted to be an upstream regulator based on the downstream differential abundance of
 REG1B, REG3A, LPS-binding protein (LBP), and transglutaminase 3 (TGM3). IL-22, through

391 STAT3-dependent signaling [61], is involved in intestinal barrier protection and induces 392 proliferation in intestinal stem cells and goblet cell proliferation in the crypts [62]. Of note, STAT3 393 is activated by cytokines other than IL-22, such as IL-6 and IL-10 family cytokines [63]. The 394 redundancy in these pathways makes it difficult to pinpoint the upstream mediators without 395 mechanistic data; however, the increased abundance of these intestinal proteins in the urine of 396 infants with NEC indicates a potential increase in signaling via STAT3 activating cytokines 397 and/or is reflective of a weakened gut barrier in patients with NEC. Additionally, hepcidin (HAMP), which had a 3-fold increased abundance in the samples from infants with NEC, is an 398 399 antimicrobial iron sequestering protein and is also positively regulated by IL-22 [64]. Moreover, 400 IL-22 is a complex and polyfunctional cytokine. We have previously shown that administration of 401 recombinant IL-22 is protective against intestinal injury during experimental NEC in mice [42]; 402 however, further studies are needed to determine the balance between protective and inflammatory roles for this cytokine in NEC. 403

404

#### 405 Conclusion

Due to the rapid and unpredictable onset of NEC, a biomarker needs to be readily available, non-invasive, rapidly tested, and able to identify NEC prior to the advanced Bell's stages. In this study, we identify proteins of interest that have the potential to serve as biomarkers that are so urgently needed to improve the care of infants with NEC. While our results need to be validated in a large cohort of infants with diverse physiologic and inflammatory conditions, this study will serve as an important foundation for future studies on a larger, diverse cohort.

#### 413

### 414 List of abbreviations

- 415 Necrotizing enterocolitis (NEC), receiver operator characteristics (ROC), area under the curve
- 416 (AUC), relative fluorescence units (RFU), false discovery rate (FDR), Ingenuity pathway
- 417 analysis (IPA), Upstream regulator analysis (URA), and Causal analysis (CNA).

418

### 419 **Declarations**

## 420 Ethics approval and consent to participate

421 After consent was obtained, samples were prospectively collected from infants admitted to the

422 St. Louis Children's Hospital Neonatal Intensive Care Unit (NICU) in St. Louis, Missouri, USA.

423 Enrollment was conducted according to protocols approved by the Washington University in St.

424 Louis School of Medicine Institutional Review Board (IRB protocol numbers 201706182 and

425 201802101).

426

## 427 Funding

428 LCF is supported by a Thrasher Research Fund Early Career Award, UNC School of Medicine

429 Physician Scientist Training Program Faculty Award, and UNC Children's Development Early

- 430 Career Investigator Grant through the generous support of donors to UNC. MG is supported by
- 431 National Institutes of Health (NIH) grants R01DK124614, R01DK118568, R01HD105301,
- 432 R44HD110306, the Chan Zuckerberg Initiative Grant number 2022-316749, and the University
- 433 of North Carolina at Chapel Hill Department of Pediatrics.

#### 434

## 435 Availability of data and materials

- 436 All data generated or analyzed during this study are included in this published article and its
- 437 supplementary information files.

438

#### 439 **Disclosure statement**

440 The authors report that there are no competing interests to declare.

441

## 442 Authors contributions

- 443 Manuscript preparation by SM, LF, CM, and MG. Critical review of the manuscript by all authors.
- 444 Data analysis by SM and LF. Research coordination and sample processing by QG, OD, GB,
- and MG. Study design by SM, LF, and MG.

446

## 447 Acknowledgements

- 448 We want to thank the neonates and families who participated in our study. We would also like to
- thank the staff at St. Louis Children's Hospital Neonatal Intensive Care Unit in St. Louis,
- 450 Missouri, USA, for all their hard work in helping to collect samples, which made this study
- 451 possible.

452

#### 454 Figure Legends

455 **Graphical abstract.** Overview of study findings. Created with Biorender.com

456

- 457 Figure 1. Volcano plots depicting the relative abundance of urine proteins in infants with
- 458 and without NEC. Urine protein levels were compared between infants with and without NEC in
- 459 the (**A**) Age-matched cohort (n = 8 pairs), (**B**) Self-matched cohort (n = 12 pairs), or (**C**) both
- 460 groups combined (*n* = 20 pairs). Differentially abundant proteins are presented on a volcano plot
- with a median fold change of RFU values ( $Log_2 \pm 1.1$ ) and *P*-value ( $-Log_{10}$  Mann Whitney U-test,
- 462 *P* = 0.05) depicted as red lines. Proteins of interest are labeled red (Protein panel 1) or blue
- 463 (Protein panel 2). REG1B was included in both panels.

464

## 465 Figure 2. Correlation between relative protein levels in the urine of infants with and

466 without NEC. (A) Spearman's *r* correlation was used to determine the correlation of relative

467 protein abundance for the entire cohort (n = 20 pairs). The directionality of the median fold

468 change for NEC vs. non-NEC is depicted by red (increased) and blue (decreased) arrows.

469 Protein panel 1 (•). Protein panel 2 (•). REG1B was included in both panels. Correlation

470 matrices were generated for protein panels 1 (**B**) and 2 (**C**).

471

### 472 Figure 3. Relative protein levels in matched urine samples for pairs of infants with and

473 without NEC cluster based on Bell's Stage, a marker of NEC severity. Hierarchical cluster

analysis demonstrating median fold change in protein abundance for sample pairs. The

directionality of the median fold change for NEC vs. control is depicted by red (increased) and
blue (decreased) arrows. Protein panel 1 (•). Protein panel 2 (•). The black box delineates
patients with Bell's Stage III NEC.

478

479	Figure 4. Urine proteins in protein panel 1 differ between infants with NEC and controls,
480	as well as based on Bell's stage. The proteins in panel 1 include REG1B, REG3A, DEFA5,
481	and FABP2. (A) Comparison of protein abundance for infants with NEC and controls. Line
482	indicates median. Dots indicate individual infants. * $P < 0.05$ , ** $P < 0.01$ by non-parametric
483	Wilcoxon test. (B) Samples were stratified based on disease severity using modified Bell's
484	stage. Line indicates median. Dots indicate individual infants. ns, $P > 0.05$ , * $P < 0.05$ , **
485	P < 0.01, *** $P < 0.0005$ , **** $P < 0.0001$ by Kruskal Wallis. ( <b>C</b> ) ROC curves with AUC values
486	and 95% CI.

487

Figure 5. Urine proteins in protein panel 2 differ between infants with NEC and controls, as well as based on Bell's stage. (A) Comparison of protein abundance for infants with NEC and controls. Line indicates median. Dots indicate individual infants. \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.005, \*\*\*\* P < 0.0001 by non-parametric Wilcoxon test. (B) Samples were stratified based on disease severity using modified Bell's stage. Line indicates median. Dots indicate individual infants. \* P < 0.05, \*\* P < 0.01, \*\*\* P < 0.005 by Kruskal Wallis. (C) ROC curves with AUC values and 95% Cl.

496	Figure 6. Combinations of select urine proteins very effectively discriminate between
497	infants with and without NEC. Combined ROC curves were generated for (A) Protein panel 1
498	(REG1B, REG3A, DEFA5, and FABP2), ( <b>B</b> ) Protein panel 2 (REG1B, SSBP1, CRYZL1, ITM2B,
499	IL36B, and IL36RN) and ( <b>C</b> ) IL-36 and IL36RN. AUC values with the 95% CI are shown.
500	
501	Supplementary Figure S1. ELISA validation of urine protein levels for controls and
502	infants with NEC. (A) REG1B, (B) REG3A, (C) DEFA5, and (D) FABP2 were measured in the
503	urine of all infants in the study via ELISA. Samples with protein levels below the limit of
504	detection were censored. Bar indicates median. n = number of patients with detectable urine
505	protein. ns, <i>P</i> > 0.05, * <i>P</i> < 0.05, ** <i>P</i> < 0.01 via Mann Whitney U-test.
506	
507	Supplementary Figure S2. IL-22 and STAT3 are upstream regulators of proteins that are
508	differentially abundant in the urine of infants with and without NEC. (A) Upstream regulator
509	analysis (URA) predicted IL-22 as a direct regulator based on the downstream state of REG1B
510	
	(+), REG3A (+), LBP (+), and TGM3 (-). (B) Causal network analysis (CNA) mapped indirect
511	(+), REG3A (+), LBP (+), and TGM3 (-). ( <b>B</b> ) Causal network analysis (CNA) mapped indirect relationships, which included IL-22 and STAT3. Proteins marked in red and green were
511 512	(+), REG3A (+), LBP (+), and TGM3 (-). ( <b>B</b> ) Causal network analysis (CNA) mapped indirect relationships, which included IL-22 and STAT3. Proteins marked in red and green were increased and decreased, respectively. Orange and blue proteins and interactions indicate
511 512 513	<ul> <li>(+), REG3A (+), LBP (+), and TGM3 (-). (B) Causal network analysis (CNA) mapped indirect</li> <li>relationships, which included IL-22 and STAT3. Proteins marked in red and green were</li> <li>increased and decreased, respectively. Orange and blue proteins and interactions indicate</li> <li>predicted activation and inhibition, respectively. Yellow and grey lines indicate interactions that</li> </ul>
511 512 513 514	<ul> <li>(+), REG3A (+), LBP (+), and TGM3 (-). (B) Causal network analysis (CNA) mapped indirect</li> <li>relationships, which included IL-22 and STAT3. Proteins marked in red and green were</li> <li>increased and decreased, respectively. Orange and blue proteins and interactions indicate</li> <li>predicted activation and inhibition, respectively. Yellow and grey lines indicate interactions that</li> <li>are inconsistent or not predicted with the state of the downstream molecule. Dashed and solid</li> </ul>
511 512 513 514 515	<ul> <li>(+), REG3A (+), LBP (+), and TGM3 (-). (B) Causal network analysis (CNA) mapped indirect</li> <li>relationships, which included IL-22 and STAT3. Proteins marked in red and green were</li> <li>increased and decreased, respectively. Orange and blue proteins and interactions indicate</li> <li>predicted activation and inhibition, respectively. Yellow and grey lines indicate interactions that</li> <li>are inconsistent or not predicted with the state of the downstream molecule. Dashed and solid</li> <li>lines indicate indirect and direct relationships, respectively.</li> </ul>

#### 517 References

- 518 [1] Battersby C, Santhalingam T, Costeloe K, et al. Incidence of neonatal necrotising
   519 enterocolitis in high-income countries: a systematic review. Arch Dis Child Fetal
   520 Neonatal Ed. 2018 Mar;103(2):F182-f189.
- 521 [2] Goldstein GP, Sylvester KG. Biomarker Discovery and Utility in Necrotizing Enterocolitis. 522 Clinics in Perinatology. 2019 2019/03/01/;46(1):1-17.
- [3] Nagpal R, Tsuji H, Takahashi T, et al. Gut dysbiosis following C-section instigates higher
   colonisation of toxigenic Clostridium perfringens in infants. Benef Microbes. 2017 May
   30;8(3):353-365.
- 526 [4] Adams JM, Valentine CJ, Karns RA, et al. DHA Supplementation Attenuates
   527 Inflammation-Associated Gene Expression in the Mammary Gland of Lactating Mothers
   528 Who Deliver Preterm. J Nutr. 2022 Jun 9;152(6):1404-1414.
- 529 [5] Sampah MES, Hackam DJ. Dysregulated Mucosal Immunity and Associated 530 Pathogeneses in Preterm Neonates. Front Immunol. 2020;11:899.
- 531 [6] Singh DK, Miller CM, Orgel KA, et al. Necrotizing enterocolitis: Bench to bedside
  532 approaches and advancing our understanding of disease pathogenesis [Review].
  533 Frontiers in Pediatrics. 2023 2023-January-11;10.
- 534[7]Wang K, Tao G, Sun Z, et al. Recent Potential Noninvasive Biomarkers in Necrotizing535Enterocolitis. Gastroenterol Res Pract. 2019;2019:8413698.
- 536 [8]Wang K, Tao G, Sun Z, et al. Recent Potential Noninvasive Biomarkers in Necrotizing537Enterocolitis. Gastroenterology Research and Practice. 2019 2019/04/22;2019:8413698.
- Agakidou E, Agakidis C, Gika H, et al. Emerging Biomarkers for Prediction and Early
   Diagnosis of Necrotizing Enterocolitis in the Era of Metabolomics and Proteomics. Front
   Pediatr. 2020;8:602255.
- 541 [10]Donda K, Torres BA, Maheshwari A. Non-coding RNAs in Neonatal Necrotizing542Enterocolitis. Newborn (Clarksville). 2022 Jan-Mar;1(1):120-130.
- 543 [11] Galley JD, Mar P, Wang Y, et al. Urine-derived extracellular vesicle miRNAs as possible
   544 biomarkers for and mediators of necrotizing enterocolitis: A proof of concept study.
   545 Journal of Pediatric Surgery. 2021 2021/11/01/;56(11):1966-1975.
- Liu Y, Jiang L-F, Zhang R-P, et al. Clinical significance of FABP2 expression in newborns
   with necrotizing enterocolitis. World Journal of Pediatrics. 2016 2016/05/01;12(2):159 165.
- [13] Chaaban H, Markel TA, Canvasser J, et al. Biobanking for necrotizing enterocolitis:
   Needs and standards. J Pediatr Surg. 2020 Jul;55(7):1276-1279.
- [14] Ralls MW, Gadepalli SK, Sylvester KG, et al. Development of the necrotizing
   enterocolitis society registry and biorepository. Semin Pediatr Surg. 2018 Feb;27(1):25 28.
- [15] Soomro S, Venkateswaran S, Vanarsa K, et al. Predicting disease course in ulcerative
   colitis using stool proteins identified through an aptamer-based screen. Nat Commun.
   2021 Jun 28;12(1):3989.
- Vanarsa K, Castillo J, Wang L, et al. Comprehensive proteomics and platform validation
   of urinary biomarkers for bladder cancer diagnosis and staging. BMC Medicine. 2023
   2023/04/05;21(1):133.

- 560 [17] Dong L, Watson J, Cao S, et al. Aptamer based proteomic pilot study reveals a urine signature indicative of pediatric urinary tract infections. PLoS One. 2020;15(7):e0235328.
  563 [18] Billing AM, Ben Hamidane H, Bhagwat AM, et al. Complementarity of SOMAscan to LC-MS/MS and RNA-seq for quantitative profiling of human embryonic and mesenchymal stem cells. J Proteomics. 2017 Jan 6;150:86-97.
- [19] Neu J, Modi N, Caplan M. Necrotizing enterocolitis comes in different forms: Historical
   perspectives and defining the disease. Semin Fetal Neonatal Med. 2018 Dec;23(6):370 373.
- Bell MJ, Ternberg JL, Feigin RD, et al. Neonatal necrotizing enterocolitis. Therapeutic decisions based upon clinical staging. Ann Surg. 1978 Jan;187(1):1-7.
- 571 [21] Walsh MC, Kliegman RM. Necrotizing enterocolitis: treatment based on staging criteria.
   572 Pediatr Clin North Am. 1986 Feb;33(1):179-201.
- 573 [22] Gold L, Ayers D, Bertino J, et al. Aptamer-based multiplexed proteomic technology for 574 biomarker discovery. PLoS One. 2010 Dec 7;5(12):e15004.
- 575 [23] Krämer A, Green J, Pollard J, Jr., et al. Causal analysis approaches in Ingenuity 576 Pathway Analysis. Bioinformatics. 2014 Feb 15;30(4):523-30.
- Lee SY, Reichlin A, Santana A, et al. TRAF2 is essential for JNK but not NF-kappaB
   activation and regulates lymphocyte proliferation and survival. Immunity. 1997
   Nov;7(5):703-13.
- 580 [25] Kuiken HJ, Egan DA, Laman H, et al. Identification of F-box only protein 7 as a negative 581 regulator of NF-kappaB signalling. J Cell Mol Med. 2012 Sep;16(9):2140-9.
- 582[26]Carballo E, Lai WS, Blackshear PJ. Feedback inhibition of macrophage tumor necrosis583factor-alpha production by tristetraprolin. Science. 1998 Aug 14;281(5379):1001-5.
- Jantos-Siwy J, Schiffer E, Brand K, et al. Quantitative urinary proteome analysis for
   biomarker evaluation in chronic kidney disease. J Proteome Res. 2009 Jan;8(1):268-81.
- 586[28]Sylvester KG, Moss RL. Urine biomarkers for necrotizing enterocolitis. Pediatr Surg Int.5872015 May;31(5):421-9.
- 588 [29] Sanderson K, O'Shea TM, Kistler CE. An Individualized Approach to Kidney Disease
   589 Screening in Children With a History of Preterm Birth. Clin Pediatr (Phila). 2023
   590 Jun;62(5):385-388.
- 591 [30]Horváth J, Wullt B, Naber KG, et al. Biomarkers in urinary tract infections which ones592are suitable for diagnostics and follow-up? GMS Infect Dis. 2020;8:Doc24.
- 593 [31]Vaidya R, Yi J, O'Shea T, et al. Long-Term Outcome of Necrotizing Enterocolitis and594Spontaneous Intestinal Perforation. Pediatrics. 2022 10/06;150.
- 595 [32] Cash HL, Whitham CV, Behrendt CL, et al. Symbiotic bacteria direct expression of an intestinal bactericidal lectin. Science. 2006 Aug 25;313(5790):1126-30.
- [33] Sun C, Wang X, Hui Y, et al. The Potential Role of REG Family Proteins in Inflammatory
   and Inflammation-Associated Diseases of the Gastrointestinal Tract. Int J Mol Sci. 2021
   Jul 3;22(13).
- 600[34]Mukherjee S, Hooper Lora V. Antimicrobial Defense of the Intestine. Immunity. 20156012015/01/20/;42(1):28-39.
- [35] van Beelen Granlund A, Østvik AE, Brenna Ø, et al. REG gene expression in inflamed
   and healthy colon mucosa explored by in situ hybridisation. Cell Tissue Res. 2013
   Jun;352(3):639-46.

605	[36]	Egozi A, Olaloye O, Werner L, et al. Single-cell atlas of the human neonatal small
606		intestine affected by necrotizing enterocolitis. PLOS Biology. 2023;21(5):e3002124.
607	[37]	Peterson KM, Guo X, Elkahloun AG, et al. The expression of REG 1A and REG 1B is
608		increased during acute amebic colitis. Parasitol Int. 2011 Sep;60(3):296-300.
609	[38]	Zhang MY, Wang J, Guo J. Role of Regenerating Islet-Derived Protein 3A in
610		Gastrointestinal Cancer. Front Oncol. 2019;9:1449.
611	[39]	Peterson KM, Buss J, Easley R, et al. REG1B as a predictor of childhood stunting in
612		Bangladesh and Peru. Am J Clin Nutr. 2013 May;97(5):1129-33.
613	[40]	Bein A, Fadel CW, Swenor B, et al. Nutritional deficiency in an intestine-on-a-chip
614		recapitulates injury hallmarks associated with environmental enteric dysfunction. Nat
615		Biomed Eng. 2022 Nov;6(11):1236-1247.
616	[41]	Rae J, Hackney J, Huang K, et al. Identification of an IL-22-Dependent Gene Signature
617		as a Pharmacodynamic Biomarker. International Journal of Molecular Sciences.
618		2021;22(15):8205.
619	[42]	Mihi B, Gong Q, Nolan LS, et al. Interleukin-22 signaling attenuates necrotizing
620		enterocolitis by promoting epithelial cell regeneration. Cell Rep Med. 2021 Jun
621		15;2(6):100320.
622	[43]	Huang X, Zhou Y, Sun Y, et al. Intestinal fatty acid binding protein: A rising therapeutic
623		target in lipid metabolism. Prog Lipid Res. 2022 Jul;87:101178.
624	[44]	Lau E, Marques C, Pestana D, et al. The role of I-FABP as a biomarker of intestinal
625		barrier dysfunction driven by gut microbiota changes in obesity. Nutrition & Metabolism.
626		2016;13.
627	[45]	Reisinger KW, Derikx JPM, Thuijls G, et al. Noninvasive measurement of intestinal
628		epithelial damage at time of refeeding can predict clinical outcome after necrotizing
629		enterocolitis. Pediatric Research. 2013 2013/02/01;73(2):209-213.
630	[46]	Ganz T. Defensins: antimicrobial peptides of innate immunity. Nat Rev Immunol. 2003
631		Sep;3(9):710-20.
632	[47]	Spencer JD, Hains DS, Porter E, et al. Human alpha defensin 5 expression in the human
633		kidney and urinary tract. PLoS One. 2012;7(2):e31712.
634	[48]	Gagne D, Shajari E, Thibault MP, et al. Proteomics Profiling of Stool Samples from
635		Preterm Neonates with SWATH/DIA Mass Spectrometry for Predicting Necrotizing
636		Enterocolitis. Int J Mol Sci. 2022 Oct 1;23(19).
637	[49]	Tremblay É, Thibault M-P, Ferretti E, et al. Gene expression profiling in necrotizing
638		enterocolitis reveals pathways common to those reported in Crohn's disease. BMC
639		Medical Genomics. 2016 2016/01/22:9(1):6.
640	[50]	Klerk DH, Plösch T, Verkaik-Schakel RN, et al. DNA Methylation of TLR4, VEGFA, and
641		DEFA5 Is Associated With Necrotizing Enterocolitis in Preterm Infants. Front Pediatr.
642		2021:9:630817.
643	[51]	Jin L. Yu B. Armando I. et al. Mitochondrial DNA-Mediated Inflammation in Acute Kidney
644		Injury and Chronic Kidney Disease. Oxidative Medicine and Cellular Longevity. 2021
645		2021/06/30:2021:9985603.
646	[52]	Tan K. Eujimoto M. Takij R. et al. Mitochondrial SSBP1 protects cells from protectoxic
647	[0-]	stresses by potentiating stress-induced HSF1 transcriptional activity Nat Commun 2015
648		Mar 12:6:6580
649	[53]	Ferat-Osorio E. Sánchez-Anava A. Gutiérrez-Mendoza M. et al. Heat shock protein 70
650	[00]	down-regulates the production of toll-like receptor-induced pro-inflammatory cytokines

651 652		by a heat shock factor-1/constitutive heat shock element-binding factor-dependent mechanism. Journal of Inflammation. 2014 2014/07/12;11(1):19.
653 654	[54]	Afrazi A, Sodhi CP, Good M, et al. Intracellular heat shock protein-70 negatively regulates TLR4 signaling in the newborn intestinal epithelium. J Immunol. 2012 May
655 656 657	[55]	1;188(9):4543-57. Ross D, Siegel D. Functions of NQO1 in Cellular Protection and CoQ10 Metabolism and its Potential Role as a Redox Sensitive Molecular Switch [Review]. Frontiers in
658		Physiology. 2017 2017-August-24:8.
659	[56]	Zhang Y, Wang O, Mi H, et al. Rhus chinensis Mill. fruits prevent necrotizing enterocolitis
660		in rat pups via regulating the expressions of key proteins involved in multiple signaling
661		pathways. J Ethnopharmacol. 2022 May 23;290:115103.
662	[57]	Wohlschlegel J, Argentini M, Michiels C, et al. First identification of ITM2B interactome in
663		the human retina. Scientific Reports. 2021 2021/08/26;11(1):17210.
664	[58]	Yuan Z-C, Xu W-D, Liu X-Y, et al. Biology of IL-36 Signaling and Its Role in Systemic
665		Inflammatory Diseases [Review]. Frontiers in Immunology. 2019 2019-October-31;10.
666	[59]	Carrier Y, Ma H-L, Ramon HE, et al. Inter-Regulation of Th1/ Cytokines and the IL-36
667		Cytokines In Vitro and In Vivo: Implications in Psoriasis Pathogenesis. Journal of
668	[00]	Investigative Dermatology. 2011 2011/12/01/;131(12):2428-2437.
669	[60]	Cho SX, Rudioff I, Lao JC, et al. Characterization of the patholmmunology of hecrotizing
670		enterocollus reveais novel inerapeutic opportunities. Nat Commun. 2020 Nov
6/1	[61]	13,11(1):5794. Sekikawa A. Eukui H. Suzuki K. at al. Involvement of the II. 22/DEC Johnsovia in
672	[01]	Jestikawa A, Fukui H, Suzuki K, et al. Involvement of the IL-22/REG laipha axis in
674	[62]	Ho GW/ Lin L. DoMartino, L. et al. Optimized human intestinal organoid model reveals
675	[02]	interleykin 22 dependency of pareth cell formation. Cell Stem Cell, 2022 Sep
676		
677	[63]	Nauven PM Putoczki TL Ernst M STAT3-Activating Cytokines: A Therapeutic
678	[00]	Opportunity for Inflammatory Bowel Disease? J Interferon Cytokine Res. 2015
679		May:35(5):340-50.
680	[64]	Ma Q. Luan J. Bai Y. et al. Interleukin-22 in Renal Protection and Its Pathological Role in
681	[]	Kidney Diseases. Front Immunol. 2022;13:851818.
682	[65]	Rushworth SA, MacEwan DJ, O'Connell MA. Lipopolysaccharide-induced expression of
683		NAD(P)H:quinone oxidoreductase 1 and heme oxygenase-1 protects against excessive
684		inflammatory responses in human monocytes. J Immunol. 2008 Nov 15;181(10):6730-7.
685	[66]	Esmon CT. The impact of the inflammatory response on coagulation. Thrombosis
686		Research. 2004 2004/01/01/;114(5):321-327.
687	[67]	Mao H, Han B, Li H, et al. FABP4 knockdown suppresses inflammation, apoptosis and
688		extracellular matrix degradation in IL-1 $\beta$ -induced chondrocytes by activating PPAR $\gamma$ to
689		regulate the NF-κB signaling pathway. Mol Med Rep. 2021 2021/12/01;24(6):855.
690	[68]	de Leeuw E, Rajabi M, Zou G, et al. Selective arginines are important for the
691		antibacterial activity and host cell interaction of human alpha-defensin 5. FEBS Lett.
692		2009 Aug 6;583(15):2507-12.
693	[69]	Schurink M, Scholten IG, Kooi EM, et al. Intestinal fatty acid-binding protein in neonates
694	1701	with imminent necrotizing enterocolitis. Neonatology. 2014;106(1):49-54.
695	[70]	Coutal S, Kokesova A, Haskalova-Hogenova H, et al. Urinary I-FABP, L-FABP, TFF-3,
696		and SAA Can Diagnose and Predict the Disease Course in Necrotizing Enterocolitis at

697 698		the Early Stage of Disease. Journal of Immunology Research. 2020 2020/03/03:2020:3074313.
699 700	[71]	Chen CC, Llado V, Eurich K, et al. Carbohydrate-binding motif in chitinase 3-like 1
/00 701		(CHI3L1/YKL-40) specifically activates Akt signaling pathway in colonic epithelial cells.
702	[72]	Schlapbach LJ. Aebi C. Fisch U. et al. Higher Cord Blood Levels of Mannose-Binding
703	[. –]	Lectin-Associated Serine Protease-2 in Infants With Necrotising Enterocolitis. Pediatric
704		Research. 2008 2008/11/01;64(5):562-566.
705	[73]	Sylvester KG, Ling XB, Liu GY, et al. Urine protein biomarkers for the diagnosis and
706		prognosis of necrotizing enterocolitis in infants. J Pediatr. 2014 Mar;164(3):607-12 e1-7.
707	[74]	Visscher MO, Carr AN, Narendran V. Epidermal Immunity and Function: Origin in
708		Neonatal Skin [Review]. Frontiers in Molecular Biosciences. 2022 2022-June-08;9.
709	[75]	Chau S, Gao J, Diao AJ, et al. Diverse yeast antiviral systems prevent lethal
/10 711		pathogenesis caused by the L-A mycovirus. Proceedings of the National Academy of Sciences 2023:120(11):e2208695120
712	[76]	Febr AR Singh SA Kerr CM et al. The impact of PARPs and ADP-ribosvlation on
713	[. •]	inflammation and host-pathogen interactions. Genes Dev. 2020 Mar 1:34(5-6):341-359.
714	[77]	Williams D, Mahmoud M, Liu R, et al. Stable flow-induced expression of KLK10 inhibits
715		endothelial inflammation and atherosclerosis. eLife. 2022 2022/01/11;11:e72579.
716	[78]	Czyzyk J, Henegariu O, Preston-Hurlburt P, et al. Enhanced Anti-Serpin Antibody Activity
717		Inhibits Autoimmune Inflammation in Type 1 Diabetes. The Journal of Immunology.
718		2012;188(12):6319-6327.
719	[79]	Chamberlain PP, Qian X, Stiles AR, et al. Integration of inositol phosphate signaling
720		pathways via human ITPK1. J Biol Chem. 2007 Sep 21;282(38):28117-25.
721	[80]	Luke CJ, Pak SC, Askew YS, et al. An intracellular serpin regulates necrosis by inhibiting
722	[04]	the induction and sequelae of lysosomal injury. Cell. 2007 Sep 21;130(6):1108-19.
723	[81]	Lee YJ, Park SY, Park EK, et al. Unique cartilage matrix-associated protein regulates
724		hinding. Piocham Piocham Rep Commun. 2010 Apr 2:511(2):221.227
725	1001	Los SP. Hos. H. Jo SI. et al. Progesterano recenter membrano component 1 reduces
720	lozi	cardiac staatosis and linetoxicity via activation of fatty acid oxidation and mitochondrial
727		respiration Sci Rep 2021 Apr 22:11(1):8781
720	[83]	Luo K Zhang L Liao Y et al. Effects and mechanisms of Eps8 on the biological
730	[00]	behaviour of malignant tumours (Review). Oncol Rep. 2021 2021/03/01:45(3):824-834.
731	[84]	Pan W. Nagpal K. Suárez-Fuevo A. et al. The Regulatory Subunit PPP2R2A of PP2A
732		Enhances Th1 and Th17 Differentiation through Activation of the GEF-H1/RhoA/ROCK
733		Signaling Pathway. J Immunol. 2021 Apr 15;206(8):1719-1728.
734	[85]	Kerr SC, Fieger CB, Snapp KR, et al. Endoglycan, a member of the CD34 family of
735		sialomucins, is a ligand for the vascular selectins. J Immunol. 2008 Jul 15;181(2):1480-
736		90.
737	[86]	Zhu C, Liu C, Chai Z. Role of the PADI family in inflammatory autoimmune diseases and
738		cancers: A systematic review. Front Immunol. 2023;14:1115794.
739	[87]	Abbasogiu A, Sarialiogiu F, Yazici N, et al. Serum Neuron-specific Enolase Levels in
740		Preterm and Term Newborns and In Infants 1–3 Months of Age. Pediatrics &
741		Neonatology. 2015 2015/04/01/;56(2):114-119.

- [88] Lin SN, Musso A, Wang J, et al. Human intestinal myofibroblasts deposited collagen VI
   enhances adhesiveness for T cells A novel mechanism for maintenance of intestinal
   inflammation. Matrix Biol. 2022 Nov;113:1-21.
- [89] Lin H, Zeng W, Lei Y, et al. Tuftelin 1 (TUFT1) Promotes the Proliferation and Migration
  of Renal Cell Carcinoma via PI3K/AKT Signaling Pathway. Pathol Oncol Res.
  2021;27:640936.
- Grover R, Burse SA, Shankrit S, et al. Myg1 exonuclease couples the nuclear and
   mitochondrial translational programs through RNA processing. Nucleic Acids Res. 2019
   Jun 20;47(11):5852-5866.
- [91] Ma J, Wei K, Liu J, et al. Glycogen metabolism regulates macrophage-mediated acute
   inflammatory responses. Nat Commun. 2020 Apr 14;11(1):1769.
- [92] Koyama S, Akbay EA, Li YY, et al. STK11/LKB1 Deficiency Promotes Neutrophil
   Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the
   Lung Tumor Microenvironment. Cancer Res. 2016 Mar 1;76(5):999-1008.
- [93] Sodhi CP, Shi XH, Richardson WM, et al. Toll-like receptor-4 inhibits enterocyte
   proliferation via impaired beta-catenin signaling in necrotizing enterocolitis.
- 758 Gastroenterology. 2010 Jan;138(1):185-96.
- 759

760

Samp	le ID	Pregnancy and delivery details					Disease severity		Surgical intervention		
Sample ID	NEC/ Control	Gestational age range (weeks)	Biological sex	Birth weight (g)	Route of delivery	NEC	Highest Bell's stage	Radiologic Findings	Surgical NEC	Final disposition	
Age-Match	ed					•					
AM 1	N	23 - 27	Male	480	CS	Yes	IIB	PN		Death, LD	
AM 1	С	33 - 37	Female	1940	V	No				Discharged	
AM 2	Ν	33 - 37	Female	2360	CS	Yes	IIA	PN		Discharged	
AM 2	С	33 - 37	Female	1740	CS	No				Discharged	
AM 3	N	33 - 37	Female	2330	CS	Yes	IIB	PN. PVG		Discharged	
AM 3	C	33 - 37	Male	2360	CS	No		,		Discharged	
AM 4	N	23 - 27	Male	640	CS	Yes	IIB	PN		Discharged	
AM 4	C	23 - 27	Female	710	CS	No				Discharged	
AM 5	N	28 - 32	Female	1190	CS	Yes	IIB	PN, PVG		Discharged	
AM 5	C	33 - 37	Male	2030	V	No		111,110		Discharged	
AM 6	N	23 - 27	Male	700	CS.	Yes	IIIB	G	PR PD	Death I D	
AM 6	C	23 - 27	Male	1150	V	No	ine	0	1 N, 1 D	Discharged	
	N	28 - 32	Female	1870	ČS.	Yes	IIΔ	PN		Discharged	
	C	20 - 32	Female	2320		No	1175	1 1 1		Discharged	
	N	20-52	Fomale	700	V	Voc		DN		Discharged	
	N C	23 - 21	Mala	1580	V	No	IID	FIN		Discharged	
Solf Motob		20 - 32	Iviale	1300	V	INU				Dischargeu	
Sen-watch	eu			1000	~~	.,		<b>B</b> 11 <b>B</b> 1/6		<b>5</b>	
SM 9	C+N	28 - 32	Male	1220	cs	Yes	IIIA	PN, PVG		Discharged	
SM10	C+N	23 - 27	Female	760	V CS	Yes		PN, PVG, P	PD	Death, NEC	
SM12	C+N	23 - 27	Male	700	CS CS	Yes	IIIR	P	PR	Discharged	
SM13	C+N	28 - 32	Female	1775	V	Yes	IB			Discharged	
SM14	C+N	28 - 32	Male	1780	ĊS	Yes	IIB	PN		Discharged	
SM15	C+N	23 - 27	Female	690	CS	Yes	П			Study closed	
SM16	C+N	23 - 27	Male	430	CS	Yes	IIB	PN		Death, LD	
SM17	C+N	28 - 32	Male	1770	CS	Yes	IIB	PN		Discharged	
SM18	C+N	23 - 27	Female	710	CS	Yes	IIA	PN		Discharged	
SM19	C+N	23 - 27	Male	530	CS	Yes	IIIA	G	00	Death, LD	
SM20	C+N	23 - 27	Male	660	CS	Yes	IIIB	PVG	PR	Study closed	

Table 1. Study cohort characteristics

Delivery route: CS = cesarean Section, V = vaginal; Surgical NEC: PR = partial resection, PD = peritoneal drain; Disposition: LD = lung disease, Radiological findings: PN = pneumatosis, PVG = portal venous gas, P = pneumoperitoneum, G = gasless abdomen, Study closed = PI relocation.

Protein name Enrichment		ichment		Protein Function	Accuracy	REF		
Entrez	UniProt	Median	Consensus tissue	Consensus localization	Role in inflammation			
Gene	ID	fold	enrichment	enrichment		Anti-microbial, Non-specific inflammation,		
Increased		change						
REG1B	P48304	9.2	Intestine, pancreas	Secreted locally	<b>*</b> •	Putative antimicrobial properties. Regulated by STAT3. Upregulated in NEC.	0.82 (0.69-0.95)	[36]
SSBP1	Q04837	5.7	Ubiquitous	Mitochondrial		Critical regulator in mitochondrial DNA maintenance. Protects cells against proteotoxic stress	0.83 (0.70-0.96)	[52]
CRYZL1	O95825	3.7	Ubiquitous	Intracellular		Lipopolysaccharide (LPS)-induced expression mitigates pro-inflammatory responses in human monocytes.	0.76 (0.59-0.92)	[65]
F9	P00740	3.2	Liver	Secreted to blood		An inflammatory response factor involved in the intrinsic blood coagulation pathway by activating factor X.	0.67 (0.50-0.84)	[66]
FABP4	P15090	3.0	Adipocyte	Intracellular		Promotes inflammation. Downregulation suppresses inflammation, apoptosis, and oxidative stress.	0.69 (0.52-0.85)	[67]
HAMP	P81172	3.0	Liver	Secreted to blood		Anti-microbial activity and anti-inflammatory IL-6 mediated-iron sequestering response.	0.76 (0.61-0.91)	[46]
DEFA5	Q01523	3.0	Intestine	Locally secreted	▲●★	Paneth cell anti-microbial peptide. Induces secretion of IL-8 by intestinal epithelial cells. Increased in NEC.	0.66 (0.49-0.83)	[68]
FABP2	P12104	3.0	Intestine	Intracellular	•*	Intestinal fatty acid binding protein. Putative biomarker which correlates with NEC in urine and serum.	0.68 (0.51-0.84)	[69]
FABP1	P07148	2.8	Liver, intestine	Intracellular	<b>•</b> •	Liver fatty acid binding protein. Putative urine marker for NEC in urine.	0.63 (0.45-0.80)	[70]
CHI3L1	P36222	2.8	Macrophages	Secreted to blood	•	Pro-inflammatory signaling in colitis by AKT, TNFα, and IL-8. A putative marker for intestinal inflammation.	0.71 (0.55-0.87)	[71]
REG3A	Q06141	2.6	Intestine	Secreted locally	<b>▲ ♦ ●</b>	Increased transcription observed in NEC. Antimicrobial peptide. Regulated by IL-17.	0.79 (0.65-0.93)	[49]
C2	P06681	2.6	Liver	Secreted to blood		MASP-2, an enzyme that regulates C2 and C4 activity, is associated with the development of NEC.	0.65 (0.48-0.82)	[72]
Decreased							T	
ITM2B	Q9Y287	-9.8	Ubiquitous	Membrane		Regulates anti-microbial amyloid-beta peptide aggregation.	0.79 (0.65-0.94)	[57]
A2ML1	A8K2U0	-7.0	Squamous epithelium	Secreted locally	*	Inactivates digestive proteases by covalent binding. Putative urine marker to distinguish NEC severity.	0.74 (0.59-0.89)	[73]
IL36B	Q9NZH7	-6.1	Keratinocyte,	Secreted locally		A pro-inflammatory cytokine that triggers MAPK and NF-kB signaling pathways.	0.86 (0.75-0.98)	[58]
TGM3	Q08188	-4.3	Squamous epithelium	Secreted to blood	•	Involved in innate immunity and barrier integrity.	0.71 (0.54-0.87)	[74]
REXO2	Q9Y3B8	-3.7	Mitochondrial	Intracellular	<b></b>	A putative anti-viral exoribonuclease that preferentially degrades two nucleotide RNA and DNA.	0.78 (0.63-0.92)	[75]
ADPRS	Q9NX46	-3.7	Ubiquitous	Intracellular		Post-translational modification of ribose to proteins, ribosylation linked to immune response modulation.	0.70 (0.54-0.87)	[76]
KLK10	043240	-3.5	Ubiquitous	Secreted locally		Serine protease which can inhibit endothelial inflammation in blood vessels.	0.75 (0.60-0.90)	[77]
SERPINB13	Q9UIV8	-3.2	Squamous epithelium	Intracellular		Anti-inflammatory serine protease inhibitor.	0.65 (0.48-0.82)	[78]
ITPK1	Q13572	-3.0	Ubiquitous	Mitochondrial		Protects against TNF $\alpha$ -induced apoptosis and MLKL-mediated necroptosis.	0.81 (0.65-0.96)	[79]
SERPINB3	P29508	-3.0	Squamous epithelium	Intracellular		Cysteine protease inhibitor. Modulates immune response and regulates necrosis.	0.72 (0.55-0.88)	[80]
	Q8WVF2	-3.0	Chondrocytes	Extracellular matrix		A secretory $\gamma$ -carboxyglutamate that regulates fibrillin 2.	0.65 (0.48-0.82)	[81]
PGRMC1	000264	-3.0	Ubiquitous	Intracollular		Reduces lipotoxicity through fatty acid oxidation and mitochondrial respiration.	0.72 (0.55-0.88)	[82]
	Q90033	-2.0	Ubiquitous	Intracellular		An analog of the EGER receptor substrate has unknown involvement in the actin cytoskeleton remotening.	0.03 (0.70-0.90)	[03]
	CON752	-2.0	Ubiquitous	Intracellular		Mediates loukeeste migration by esting as a ligand for yeasylar selecting E. D. and L. selecting	0.79 (0.05-0.93)	[04]
		-2.0	Koratinoovtos	Intracellular		Involved in the differentiation of immune colls. Regulated by NE kR	0.73 (0.37-0.90)	[05]
	Q90LC0	-2.0	Keratinocytes		-	Anteresist of the IL 20 singeling in epithelial barriers. High IL 20 IL 20 DN retire abarrow in NEO	0.04 (0.47-0.01)	[00]
IL36RN	Q90BH0	-2.0	CNC and nenerose	Intracellular	-	Antagonist of the IL-36 signaling in epithelial barriers. High IL-36:IL36RN ratios observed in NEC.	0.91 (0.82-0.99)	[60]
ENU2	P09104	-2.0	Cino and particleas		Gamma enolase is the predominant CNS dimer. Elevated in serum of preterm infants.		0.78 (0.63-0.92)	[07]
		-2.0			Myotibroblasts deposit collagen VI to enhance T-cell adhesion to regulate intestinal inflammation.		0.73 (0.57-0.89)	[00]
	Q9NNX1	-2.6		Secreted locally		Involved in mesenchymal stem cell function and adaptation to hypoxia.	0.73 (0.57-0.89)	[89]
MYG1	Q9HBU/	-2.6	UDIQUITOUS	Intracellular	-	Exonuclease which cleaves in situ at specific transcripts.	0.71 (0.55-0.88)	[90]
CADO	PU0/3/	-2.0	Ubiquitous, liver		Strongly linked to inflammation through glycogen metabolism		0.70 (0.54-0.87)	[9]]
CAB39 CTNNBID1	Q9Y3/6	-2.6	Upiquitous	Intracellular	Component of a complex that binds and activates STK11/LKB1 (tumor suppressor).		0.70(0.53-0.86)	[92]
	GONORO	-2.0	Obiquitous	materiular	-	Enteropyte premeration is imparted by dampened with Tubela-catellin signaling in NEC.	0.07 (0.00-0.03)	[33]

## Table 2. Classification of differentially abundant urine proteins identified by the SomaScan® (7K) assay.

# Table 3. Ingenuity pathway upstream regulator analysis

#### Causal Network Analysis

Master Regulator	Protein Name	UniProt	Molecule Type	Predicted Activation	Activation z-score	<i>P</i> -value of overlap	Network bias- corrected <i>P</i> -value
TNFRSF1B	TNF receptor-associated factor 2	Q12933	Transmembrane receptor	Activated	2.353	1.0E-09	0.0003
ZFP36	mRNA decay activator protein ZFP36	P26651	Transcription regulator	Activated	2.263	7.4E-07	0.0153
ZC3H12A	Endoribonuclease ZC3H12A	Q5D1E8	Enzyme	Activated	2.191	1.7E-05	0.0430
IL22	Interleukin-22	Q9GZX6	Cytokine	Activated	2.000	6.9E-04	0.0171
USP11	Ubiquitin carboxyl-terminal hydrolase 11	P51784	Peptidase	Inhibited	-2.121	9.6E-07	0.0140
EML4-ALK	Tyrosine-protein kinase receptor	J7MA22	Fusion gene/product	Inhibited	-2.137	2.9E-08	0.0018
ALDH1A3	Aldehyde dehydrogenase family 1 member A3	P47895	Enzyme	Inhibited	-2.236	8.0E-06	0.0005
GRM1	Metabotropic glutamate receptor 1	Q13255	G-protein coupled receptor	Inhibited	-2.263	1.8E-05	0.0263
PLCE1	1-phosphatidylinositol 4,5-bisphosphatesphodiesterase E1	Q9P212	Enzyme	Inhibited	-2.401	6.4E-06	0.0274
RNF11	RING finger protein 11	Q9Y3C5	Enzyme	Inhibited	-2.414	4.3E-06	0.0435
SEPTIN9	Septin-9	Q9UHD8	Enzyme	Inhibited	-2.502	7.3E-06	0.0178
Upstream Regulator analysis							
Upstream	Protein name	UniProt	Molecule Type	Predicted	Activation	P-value of	
Regulator				Activation	z-score	overlap	
Esrra	Steroid hormone receptor ERR1	P11474	Ligand-dependent nuclear	Activated	2.000	0.0003	
IL22	Interleukin-22	Q9GZX6	Cytokine		1.957	0.0009	
SREBF1	Sterol regulatory element-binding protein 1	P36956	Transcription regulator		1.950	0.0001	
RXRA	Retinoic acid receptor RXR-alpha	P19793	Ligand-dependent nuclear		1.941	0.0079	
PGR	Progesterone receptor	P06401	Ligand-dependent nuclear		1.732	0.0499	
STAT3	Signal transducer and activator of transcription 3	P40763	Transcription regulator		0.736	0.0000	
HIF1A	Hypoxia-inducible factor 1-alpha	Q16665	Transcription regulator	Inhibited	-2.177	0.0013	
TNF	Tumor necrosis factor	P01375	Cytokine	Inhibited	-2.130	0.0026	
KLF6	Kruppel-like factor 6	Q99612	Transcription regulator	Inhibited	-2.000	0.0078	
TGFB1	Transforming growth factor beta-1 proprotein	P01137	Growth factor		-1.338	0.0018	
IL1B	Interleukin-1 beta	P01584	Cytokine		-1.277	0.0001	
NFE2L2	Nuclear factor erythroid 2-related factor 2	Q16236	Transcription regulator		-1.233	0.0198	
IL10RA	Interleukin-10 receptor subunit alpha	Q13651	Transmembrane receptor		-1.000	0.0123	
LPS	lipopolysaccharide		Chemical drug		-0.942	0.0000	
CTNNB1	Catenin beta-1	P35222	Transcription regulator		-0.686	0.0026	
TGM2	Protein-glutamine gamma-glutamyltransferase 2	P21980	Enzyme		-0.664	0.0005	
AHR	Aryl hydrocarbon receptor	P35869	Ligand-dependent nuclear		-0.517	0.0001	

# **Graphical abstract**













# Figure 4



Figure 5



